Cronos (CRON) Return on Invested Capital (2022 - 2023)
Cronos' (CRON) quarterly Return on Invested Capital came in at 1.43% in Q4 2023, up 44.0% year-on-year from 0.99% in Q4 2022, and down 7.2% quarter-over-quarter from 1.33% in Q3 2023.
Cronos (CRON) Return on Invested Capital (2022 - 2023) Analysis & Trends
Cronos' Return on Invested Capital history runs 2 years deep, the most recent figure standing at 1.43% for Q4 2023.
- On a quarterly basis, Return on Invested Capital rose 44.0% year-over-year to 1.43% in Q4 2023; TTM through Dec 2023 was 1.43%, a 44.0% increase from a year earlier, with the FY2022 full-year figure at 3.5%, changed N/A from the prior year.
- Return on Invested Capital slipped to 1.43% in Q4 2023 per CRON's latest filing, from 1.33% in the prior quarter.
- Across five years, Return on Invested Capital topped out at 0.27% in Q3 2022 and bottomed at 7.09% in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 0.01% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 0.01% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 0.00% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 0.00% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 0.03% |
| 10 | Cronos | 1.04 Bn | 267.78 Mn | 19.15 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -1.43% |
| Sep 30, 2023 | -1.33% |
| Jun 30, 2023 | -1.11% |
| Mar 31, 2023 | -1.36% |
| Dec 31, 2022 | -1.87% |
| Sep 30, 2022 | 0.27% |
| Jun 30, 2022 | -0.27% |
| Mar 31, 2022 | -7.09% |